24 studies found for:    17237035 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Conditions: Carcinoma, Squamous;   Head and Neck Cancer;   Oral Cancer;   Laryngeal Cancer;   Pharyngeal Cancer
Interventions: Drug: Bortezomib (Velcade, PS-341);   Drug: Cetuximab;   Drug: Cisplatin;   Procedure: Radiation Therapy
2 Recruiting Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Condition: Leukemia, Hairy Cell
Interventions: Drug: moxetumomab pasudotox;   Drug: IV Bag Protectant for Moxetumomab pasudotox
3 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
4 Recruiting Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Conditions: Metastatic Cancer;   Melanoma
Interventions: Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
5 Completed
Has Results
Sunitinib to Treat Recurrent Brain Cancer
Conditions: Glioblastoma Multiforme;   Malignant Gliomas;   Anaplastic Gliomas
Intervention: Drug: Sutent (sunitinib)
6 Recruiting A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
7 Recruiting A Phase II Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Comparing Two Different Chemotherapy Preparative Regimens
Condition: Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (young TIL)
8 Active, not recruiting Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease
Conditions: Squamous Cell Lung Cancer;   Lung Cancer;   Pulmonary Disease
Intervention: Device: Optical Frequency Domain Imaging (OFDI) System
9 Terminated
Has Results
TRC105 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: TRC105
10 Completed
Has Results
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
Conditions: NSCLC;   Solid Tumors
Interventions: Drug: YM155;   Drug: Carboplatin;   Drug: Paclitaxel
11 Active, not recruiting Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Condition: Metastatic Breast Cancer
Intervention: Drug: Avastin + mFOLFOX6
12 Unknown  Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Procedure: FDG-/FLT-PET
13 Terminated
Has Results
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: Pioglitazone
14 Completed
Has Results
PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue
Condition: Healthy
Interventions: Drug: Testosterone gel;   Drug: Dutasteride;   Drug: Depo-Medroxyprogesterone (DMPA);   Other: Placebo Testosterone gel;   Other: Placebo dutasteride;   Other: Placebo DMPA
15 Recruiting Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]
Condition: Squamous Cell Carcinoma of the Penis
Intervention: Procedure: MRI-PET
16 Recruiting Study of Cell Transfer Therapy for Metastatic Melanoma Using 4-1BB Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
17 Active, not recruiting Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
18 Recruiting 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
Condition: Lymphoma
Interventions: Procedure: Biopsy;   Radiation: Fluordeoxyglucose F 18;   Other: [3'-deoxy-3'-[F-18] fluorothymidine;   Procedure: computed tomography;   Procedure: fine-needle aspiration
19 Terminated
Has Results
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
20 Suspended Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Conditions: Skin Cancer;   Metastatic Melanoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IL-12 transduced TIL

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years